Literature DB >> 20029415

Methodology for randomized trials of patients with nonvariceal upper gastrointestinal bleeding: recommendations from an international consensus conference.

Loren Laine1, Brennan Spiegel, Alaa Rostom, Paul Moayyedi, Ernst J Kuipers, Marc Bardou, Joseph Sung, Alan N Barkun.   

Abstract

The aim of this document is to provide a methodological framework for the design, performance, analysis, interpretation, and communication of randomized trials that assess management of patients with nonvariceal upper gastrointestinal bleeding. Literature searches were performed and an iterative process with electronic and face-to-face meetings was used to achieve consensus among panel members as part of an International Consensus Conference on Nonvariceal Upper Gastrointestinal Bleeding. Recommendations of the panel include the following. Randomized trials must explicitly state their primary hypothesis. A nonmanipulable randomization schedule with concealed allocation should be used. Stratification (e.g., for age and stigmata of hemorrhage) may be considered, especially in smaller studies. The patient and personnel providing care or recording information should be blinded. Inclusion criteria should be overt bleeding with endoscopy performed within 24 h or less. One type of lesion (e.g., ulcer) should be studied with stigmata to be included predefined. Use of placebo/no therapy vs. active controls depends on current standard practice. Standardizing study and key non-study interventions should ensure uniform provision of interventions. Criteria for repeat endoscopy and subsequent interventions should be predefined. The primary end point should be further bleeding (persistent and recurrent bleeding) with primary assessment at 7 days; mortality, with primary assessment at 30 days, would be appropriate in very large trials. Sample size calculation based on assumptions regarding primary end point results with regard to study intervention and control must be provided, and all patients enrolled must be accounted for. In general, the primary population for analysis is all patients randomized, although a per-protocol population may be used if this is the more conservative approach (e.g., equivalence study).

Entities:  

Mesh:

Year:  2009        PMID: 20029415     DOI: 10.1038/ajg.2009.702

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  23 in total

Review 1.  Early Colonoscopy Does Not Improve Outcomes of Patients With Lower Gastrointestinal Bleeding: Systematic Review of Randomized Trials.

Authors:  Cynthia Tsay; Dennis Shung; Katherine Stemmer Frumento; Loren Laine
Journal:  Clin Gastroenterol Hepatol       Date:  2019-12-13       Impact factor: 11.382

2.  Endoclips vs large or small-volume epinephrine in peptic ulcer recurrent bleeding.

Authors:  Neven Ljubicic; Ivan Budimir; Alen Biscanin; Marko Nikolic; Vladimir Supanc; Davor Hrabar; Tajana Pavic
Journal:  World J Gastroenterol       Date:  2012-05-14       Impact factor: 5.742

Review 3.  Why do mortality rates for nonvariceal upper gastrointestinal bleeding differ around the world? A systematic review of cohort studies.

Authors:  Vipul Jairath; Myriam Martel; Richard F A Logan; Alan N Barkun
Journal:  Can J Gastroenterol       Date:  2012-08       Impact factor: 3.522

4.  Outcomes of Hemospray therapy in the treatment of intraprocedural upper gastrointestinal bleeding post-endoscopic therapy.

Authors:  Mohamed Hussein; Durayd Alzoubaidi; Alvaro de la Serna; Michael Weaver; Jacobo O Fernandez-Sordo; Johannes W Rey; Bu'Hussain Hayee; Edward Despott; Alberto Murino; Sulleman Moreea; Phil Boger; Jason Dunn; Inder Mainie; David Graham; Dan Mullady; Dayna Early; Krish Ragunath; John Anderson; Pradeep Bhandari; Martin Goetz; Ralf Kiesslich; Emmanuel Coron; Enrique R de Santiago; Tamas Gonda; Laurence B Lovat; Rehan Haidry
Journal:  United European Gastroenterol J       Date:  2020-06-26       Impact factor: 4.623

5.  Severity and Outcomes of Upper Gastrointestinal Bleeding With Bloody Vs. Coffee-Grounds Hematemesis.

Authors:  Loren Laine; Stig B Laursen; Liam Zakko; Harry R Dalton; Jing H Ngu; Michael Schultz; Adrian J Stanley
Journal:  Am J Gastroenterol       Date:  2018-01-30       Impact factor: 10.864

Review 6.  Intermittent vs continuous proton pump inhibitor therapy for high-risk bleeding ulcers: a systematic review and meta-analysis.

Authors:  Hamita Sachar; Keta Vaidya; Loren Laine
Journal:  JAMA Intern Med       Date:  2014-11       Impact factor: 21.873

7.  International prospective observational study of upper gastrointestinal haemorrhage: Does weekend admission affect outcome?

Authors:  Iain A Murray; Harry R Dalton; Adrian J Stanley; Jing H Ngu; Brian Maybin; Mahmoud Eid; Kenneth G Madsen; Rozeta Abazi; Hamad Ashraf; Mohamed Abdelrahim; Rebecca Lissmann; Jenny Herrod; Christopher Jl Khor; Hock S Ong; Doreen Sc Koay; Yung K Chin; Stig B Laursen
Journal:  United European Gastroenterol J       Date:  2017-03-16       Impact factor: 4.623

8.  Recommended primary outcomes for clinical trials evaluating hemostatic blood products and agents in patients with bleeding: Proceedings of a National Heart Lung and Blood Institute and US Department of Defense Consensus Conference.

Authors:  Philip C Spinella; Nahed El Kassar; Andrew P Cap; Andrei L Kindzelski; Christopher S Almond; Alan Barkun; Terry B Gernsheimer; Joshua N Goldstein; John B Holcomb; Alfonso Iorio; Dennis M Jensen; Nigel S Key; Jerrold H Levy; Stephan A Mayer; Ernest E Moore; Simon J Stanworth; Roger J Lewis; Marie E Steiner
Journal:  J Trauma Acute Care Surg       Date:  2021-08-01       Impact factor: 3.697

9.  Chronic kidney disease, hemodynamic instability, and endoscopic high-risk appearance are associated with 30-day rebleeding in patients with non-variceal upper gastrointestinal bleeding.

Authors:  Yoo Jin Lee; Eun Soo Kim; Yu Jin Hah; Kyung Sik Park; Kwang Bum Cho; Byoung Kuk Jang; Woo Jin Chung; Jae Seok Hwang
Journal:  J Korean Med Sci       Date:  2013-09-25       Impact factor: 2.153

10.  Acute gastrointestinal bleeding: proposed study outcomes for new randomised controlled trials.

Authors:  Dennis M Jensen; Alan Barkun; David Cave; Ian M Gralnek; Rome Jutabha; Loren Laine; James Y W Lau; John R Saltzman; Roy Soetikno; Joseph J Y Sung
Journal:  Aliment Pharmacol Ther       Date:  2021-07-20       Impact factor: 9.524

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.